---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002039"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:14:43.513084+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics restructures pipeline, cuts headcount 25% to extend cash runway into 2026

## Summary
- De-prioritizes CNTY-103 (glioblastoma) and discovery program; focuses on CNTY-101, CNTY-102, CNTY-107.
- Reduces headcount by ~25%; closes labs in Seattle and Hamilton, consolidates research in Philadelphia.
- Extends cash runway into 2026; Phase 1 CNTY-101 enrollment expected imminently; partnered BMS programs unaffected.
- Hy Levitsky, President of R&D, resigns effective Jan 31, 2023; Luis Borges and Adrienne Farid assume responsibilities.

## SEC filing metadata
- accession: 0001104659-23-002039
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923002039/0001104659-23-002039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923002039/tm232470d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002039
- JSON: https://secwatch.observer/filing/0001104659-23-002039.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.